Delivery Order SPE2DB22D3501-SPE2DB25FWR02
- Not listed
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 8, 2025, for the supply of Zeposia 0.92 mg capsules (30-count) with a ceiling value of $13,862.79. This firm fixed-price delivery order represents a non-competitive award and is scheduled for completion by August 29, 2025. The work will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. As a leading pharmaceutical distributor, AmerisourceBergen maintains a...
- The Defense Logistics Agency awarded a delivery order valued at $13,862.79 to AmerisourceBergen Drug Corp for the supply of Zeposia 0.92 mg capsules (30-count units) under a firm fixed-price contract. The award was issued on July 29, 2025, with an ultimate completion date of August 19, 2025, and represents a non-set-aside, competitively awarded procurement. AmerisourceBergen Drug Corp will perform the delivery from its corporate office location in Conshohocken, Pennsylvania. This delivery...
- The Defense Logistics Agency awarded a delivery order valued at $13,862.79 to AmerisourceBergen Drug Corp for Zeposia 0.92 mg capsules (30-count) on July 24, 2025, with an ultimate completion date of August 14, 2025. The contract employs firm fixed-price pricing with no set-aside designation, indicating competitive award. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, is a major pharmaceutical distributor serving federal medical procurement needs. This delivery order...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 28, 2025, for Zeposia 0.92 mg capsules (30-count units) under a firm fixed-price contract valued at $13,862.79. This non-set-aside competitive award, with an ultimate completion date of August 18, 2025, will be performed at AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. The delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 18, 2025, for the supply of Zeposia 0.92 mg capsules (30-count units) with a ceiling value of $9,241.86. This firm fixed-price delivery order, with an ultimate completion date of August 8, 2025, represents a non-set-aside competitive award supporting federal medical procurement needs. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, serves as a critical pharmaceutical distributor for...
- AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, was awarded a delivery order valued at $4,620.93 by the Defense Logistics Agency (DLA) on July 29, 2025, for the supply of Zeposia 0.92 mg capsules (30-count packaging). This is a firm fixed-price, competitively awarded contract with no set-aside designation and an ultimate completion date of August 19, 2025. The contract will be performed at AmerisourceBergen's Conshohocken facility. This delivery order is issued under...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for the supply of Zeposia 0.92 mg capsules (30-count units) under a firm fixed-price contract valued at $4,620.93, with an ultimate completion date of August 13, 2025. This non-set-aside competitive award reflects AmerisourceBergen's capability to deliver pharmaceutical products to support federal medical procurement needs. The contract is executed out of the vendor's corporate office location in Conshohocken,...
- The U.S. Defense Logistics Agency Troop Support Medical has awarded Amerisourcebergen Drug Corp, a subsidiary of Amerisourcebergen Corporation, a $4,466.57 firm fixed price delivery order contract to supply Zeposia 0.92 mg capsules. This order is issued under an indefinite delivery contract (IDC) with a potential value of $999,999,999.00 that Amerisourcebergen holds with DLA Troop Support Medical. The IDC serves as the primary vehicle for Amerisourcebergen to provide pharmaceuticals and...
- This delivery order, valued at $9,241.86, awards AmerisourceBergen Drug Corp the supply of Zeposia 0.92 mg capsules (30-count units) under a firm fixed price contract. The award was made competitively without set-aside designation and is set for completion by August 19, 2025. The Defense Logistics Agency, which handles medical supply chain procurement for the Department of Defense, is the funding federal agency, with performance taking place at AmerisourceBergen's corporate office location in...
- The U.S. Defense Logistics Agency (DLA) awarded a firm fixed price delivery order to Amerisourcebergen Drug Corp, a subsidiary of Amerisourcebergen Corporation, to supply Zeposia 0.92 mg capsules. The $4,466.57 order has an ultimate completion date of April 3, 2024. Amerisourcebergen Drug Corp is the prime contractor on an indefinite delivery contract (IDC) with DLA Troop Support Medical valued up to $999,999,999.00 through December 31, 2025. This IDC serves as the primary vehicle for...
- SPE2DB22D3501Indefinite Delivery Contract
- SPE2DB22D3501-SPE2DB25FWR02Delivery Order
The Defense Logistics Agency awarded a $13,862.79 delivery order to AmerisourceBergen Drug Corp on July 30, 2025, for the supply of Zeposia 0.92 mg capsules (30-count units). This is a firm fixed-price contract with an ultimate completion date of August 20, 2025, and represents a non-competitive set-aside delivery order under AmerisourceBergen's larger indefinite delivery contract with DLA Troop Support Medical. The product will be performed and delivered from the company's Conshohocken, Pennsylvania location, which serves as AmerisourceBergen's corporate headquarters and a major distribution hub for federal pharmaceutical procurement. This delivery order is issued under AmerisourceBergen's existing $999.999 billion indefinite delivery contract (SPE2DX) with DLA Troop Support Medical, running through December 2026. This prime vendor agreement enables the company to supply a comprehensive range of pharmaceutical products and medical supplies to support military and federal healthcare systems globally, including the Defense Health Agency and U.S. Coast Guard. Zeposia (ozanimod), an immunosuppressant used to treat multiple sclerosis and ulcerative colitis, aligns with AmerisourceBergen's portfolio of specialized neurological and immunological medications delivered through the federal medical supply chain.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $13.9k | 7/30/25 |